Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.17.4.2 extracted from

  • Odenike, O.M.; Larson, R.A.; Gajria, D.; Dolan, M.E.; Delaney, S.M.; Karrison, T.G.; Ratain, M.J.; Stock, W.
    Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia (2008), Invest. New Drugs, 26, 233-239.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 1.17.4.2

Inhibitors

Inhibitors Comment Organism Structure
3-aminopyridine-2-carboxaldehyde-thiosemicarbazone i.e. 3-AP, phase I study in combination with high dose cytarabine in patients with advanced myeloid leukemia, resulting in enhanced cytarabine cytotoxicity with possible methemoglobinemia, overview Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
 patients with advanced myeloid leukemia
-

Source Tissue

Source Tissue Comment Organism Textmining